SNY Dec 2024 42.500 call
| Previous close | 9.40 |
| Open | 9.40 |
| Bid | 11.60 |
| Ask | 14.60 |
| Strike | 42.50 |
| Expiry date | 2024-12-20 |
| Day's range | 9.40 - 9.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
ZacksRegeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - August 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
PR NewswireSanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA
Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for Children program to help ensure the majority of doses are available ahead of RSV season. The US market is anticipated to have enough supply so that every eligible baby born outside of the season will have access to immunization at a regular checkup and those born during the season will have access at bir
